6 天之前 · Stelara (ustekinumab) is used to treat Crohn's disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis. Stelara is an interleukin inhibitor that blocks IL-12 and IL-23.

If your dose is 90 mg, you will receive either one 90-mg prefilled syringe or two 45-mg prefilled syringes. If you receive two 45-mg prefilled syringes for a 90-mg dose, you will need to give …

• The recommended dosage is 45 mg administered subcutaneously initially and 4 weeks later, followed by 45 mg administered subcutaneously every 12 weeks. • For patients with co …

Of all the plaque psoriasis biologic medications, STELARA® has the fewest yearly doses. With only 4 doses a year after 2 starter doses, you have a full 12 weeks between doses. STELARA …

2025年3月17日 · The recommended dose is 45 mg initially and 4 weeks later, followed by 45 mg every 12 weeks. For patients with co-existent moderate-to-severe plaque psoriasis weighing …

STELARA ®, available as 45 mg and 90 mg, is a subcutaneous injection intended for use under the guidance and supervision of a physician with patients who wiII be closely monitored and …

2024年10月21日 · Find patient medical information for Ustekinumab (Stelara) on WebMD including its uses, side effects and safety, interactions, pictures, warnings, and user ratings

2025年2月4日 · Ustekinumab injection is used to treat plaque psoriasis, ulcerative colitis, Crohn’s disease, and psoriatic arthritis, which are autoimmune disorders. Ustekinumab injection works …

2025年3月17日 · Stelara® (ustekinumab) Injection - 45 mg/0.5 mL - For subcutaneous use - Contains one 45 mg/0.5 mL syringe - NDC 57894-060-03 - Single-dose prefilled syringe - …

STELARA® is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis. For patients weighing 100 kg or less, the recommended dose is 45 mg …